Abstract:Sortase A (SrtA) anchors surface proteins to the cell wall envelope, and it has attracted increasing interesting as a potential antivirulence target. Several small-molecule inhibitors for SrtA have been developed, but target validation remains largely underexplored. Herein, we report a new class of SrtA inhibitors that supports antivirulence therapy through small-molecule targeting of SrtA. Tideglusib (TD), a drug candidate for myotonic dystrophy, was outstanding in high-throughput screening. A concise synthetic route quickly provided TD analogues, and the structure–activity relationships for SrtA inhibition have been established from those analogues. Several compounds largely retained the in vitro potency and exhibited a better solubility than TD. Additionally, TD attenuated virulence-related phenotypes in vitro and protected mice against lethal S. aureus USA300 bacteremia. Our study indicates that TD and its analogues could be new candidates as SrtA inhibitors with potential in the development of new antivirulence agents.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00803?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00803</a>.NMR spectrum for TD analogues, representative HPLC, chemical structures of compounds used as control in this study, and no PAINS-containing properties of TD and TD32 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00803/suppl_file/jm0c00803_si_001.pdf">PDF</a>)Docking model of TD bound to SrtA (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00803/suppl_file/jm0c00803_si_002.pdb">PDB</a>)Docking model of TD32 bound to SrtA (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00803/suppl_file/jm0c00803_si_003.pdb">PDB</a>)Molecular formula strings and biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00803/suppl_file/jm0c00803_si_004.csv">CSV</a>)This article has not yet been cited by other publications.

Tideglusib Inhibits Pif1 Helicase of Bacteroides sp. via an Irreversible and Cys-380-Dependent Mechanism

Structural and Functional Insights into the Unwinding Mechanism of Bacteroides Sp Pif1

Structure-based discovery of first inhibitors targeting the helicase activity of human PIF1

Eukaryotic Pif1 Helicase Unwinds G-quadruplex and Dsdna Using a Conserved Wedge

Structural Basis for DNA Unwinding at Forked Dsdna by Two Coordinating Pif1 Helicases.

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Discovery of Bisindole As A Novel Scaffold for Protein Tyrosine Phosphatase 1b Inhibitors

Structural and functional studies of SF1B Pif1 from Thermus oshimai reveal dimerization-induced helicase inhibition

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains

Ebselen and TPI-1, as RecG helicase inhibitors, potently enhance the susceptibility of Pseudomonas aeruginosa to DNA damage agents

Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo

Design, synthesis, biological evaluation and molecular dynamics simulation studies of imidazolidine-2,4-dione derivatives as novel PTP1B inhibitors

Structural Studies of Pif1 Helicases from Thermophilic Bacteria

Structural study of the function of Candida Albicans Pif1

Identification of small-molecule inhibitors of human MUS81-EME1/2 by FRET-based high-throughput screening

Exploration and Biological Evaluation of 1,3-Diamino-7h-pyrrol[3,2-f]quinazoline Derivatives As Dihydrofolate Reductase Inhibitors.

A Small Molecule IFB07188 Inhibits Proliferation of Human Cancer Cells by Inducing G2/M Cell Cycle Arrest and Apoptosis

Identification of flexible Pif1–DNA interactions and their impacts on enzymatic activities

Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association.

Discovery of novel fructose-1,6-bisphosphatase inhibitors bearing benzimidazole scaffold using a dual-ligand molecular docking model

Tideglusib and Its Analogues As Inhibitors of Staphylococcus aureus SrtA